AOD-9604 is a synthetic peptide derived from the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added N-terminal tyrosine. It was originally developed as a research analog intended to reproduce the lipid-metabolic activity attributed to that hGH region without the full hormone’s growth-promoting effects.
It is studied primarily in the context of fat metabolism research.
In preclinical studies, AOD-9604 has been described as influencing lipid metabolism pathways, including stimulation of lipolysis and inhibition of lipogenesis in adipose tissue models, reportedly without acting through the classical growth hormone receptor or affecting IGF-1 in the manner of full-length hGH.
The precise molecular target remains an active area of investigation.
Lipolysis — studied in adipocyte and rodent models measuring fat breakdown [1].
Lipogenesis — investigated for inhibition of fat accumulation in cell models [1].
Metabolic markers — examined for effects on energy metabolism without IGF-1 elevation [2].
Cartilage and tissue research — explored in exploratory musculoskeletal studies [3].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
In rodent studies, animals received AOD-9604 and researchers measured changes in body fat and lipolytic activity in adipose tissue [1]. In a clinical safety and metabolic study, participants received the peptide and investigators monitored metabolic parameters and reported no significant IGF-1 elevation [2].
Exploratory work has also examined AOD-9604 in combination with other agents in cartilage models [3].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
SemaglutideNeutral
Different mechanism (hGH fragment vs GLP-1 agonist); combined pharmacology not established.
CJC-1295Compatible
Both relate to growth-hormone-axis research and are sometimes studied within the same experimental context.
5-Amino-1MQNeutral
Distinct metabolic target (NNMT); no established interaction data.
InsulinNeutral
No well-characterized interaction reported in the literature.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “AOD-9604”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
It is a modified fragment of human growth hormone corresponding to residues 176–191, with an added N-terminal tyrosine.
What research areas has it been studied in?
Primarily lipid metabolism—lipolysis and lipogenesis in adipose models—and some exploratory tissue studies.
Does it act like full growth hormone?
Research suggests it targets lipid-metabolic pathways without the growth-promoting IGF-1 effects of full-length hGH.
Is this material for human use?
No. It is supplied for in-vitro and laboratory research use only, not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite